MREO
Price
$4.22
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
69 days until earnings call
ZYME
Price
$12.52
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
Ad is loading...

MREO vs ZYME

Header iconMREO vs ZYME Comparison
Open Charts MREO vs ZYMEBanner chart's image
Mereo BioPharma Group
Price$4.22
Change-$0.00 (-0.00%)
Volume$1.57M
CapitalizationN/A
Zymeworks
Price$12.52
Change-$0.00 (-0.00%)
Volume$631.81K
CapitalizationN/A
View a ticker or compare two or three
MREO vs ZYME Comparison Chart
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
MREO vs. ZYME commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and ZYME is a Buy.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (MREO: $4.22 vs. ZYME: $12.52)
Brand notoriety: MREO and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 145% vs. ZYME: 75%
Market capitalization -- MREO: $649.26M vs. ZYME: $873.88M
MREO [@Biotechnology] is valued at $649.26M. ZYME’s [@Biotechnology] market capitalization is $873.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, both MREO and ZYME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 5 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • MREO’s TA Score: 5 bullish, 4 bearish.
  • ZYME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both MREO and ZYME are a good buy in the short-term.

Price Growth

MREO (@Biotechnology) experienced а -9.44% price change this week, while ZYME (@Biotechnology) price change was +3.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.38%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1.46%.

Reported Earning Dates

MREO is expected to report earnings on Nov 27, 2024.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (+7.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($874M) has a higher market cap than MREO($649M). MREO YTD gains are higher at: 82.684 vs. ZYME (20.500). MREO has higher annual earnings (EBITDA): -34.59M vs. ZYME (-105.32M). ZYME has more cash in the bank: 330M vs. MREO (87.4M). MREO has less debt than ZYME: MREO (6.16M) vs ZYME (20.1M). ZYME has higher revenues than MREO: ZYME (62.7M) vs MREO (1M).
MREOZYMEMREO / ZYME
Capitalization649M874M74%
EBITDA-34.59M-105.32M33%
Gain YTD82.68420.500403%
P/E RatioN/AN/A-
Revenue1M62.7M2%
Total Cash87.4M330M26%
Total Debt6.16M20.1M31%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
74
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MREOZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
MREO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMGJX6.870.02
+0.29%
Principal MidCap Growth J
HSMCX8.91N/A
N/A
Hartford Small Company C
DWGCX10.71-0.01
-0.09%
American Funds Dvlpg Wld Gr&Inc C
HIOIX11.62-0.02
-0.17%
Fintrust Income and Opportunity Instl
GLFOX16.63-0.07
-0.42%
Lazard Global Listed Infrastructure Open

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with MDGL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+6.84%
MDGL - MREO
37%
Loosely correlated
-0.01%
XERS - MREO
33%
Poorly correlated
+0.34%
KURA - MREO
31%
Poorly correlated
+0.50%
ARRY - MREO
30%
Poorly correlated
-5.41%
ZYME - MREO
30%
Poorly correlated
+1.79%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with BEAM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+1.79%
BEAM - ZYME
45%
Loosely correlated
-0.27%
RXRX - ZYME
45%
Loosely correlated
+2.07%
RCKT - ZYME
44%
Loosely correlated
-4.40%
ABSI - ZYME
43%
Loosely correlated
+0.76%
CRSP - ZYME
43%
Loosely correlated
-0.64%
More